Patients with arterial hypertension associated with metabolic disorders: characteristics and therapeutic approach
Abstract
Arterial hypertension (AH) is associated with metabolic disorders in approximately 80% of cases. There is a pandemic of so-called new risk factors, such as insulin resistance and association with systemic type of hyperinsulinemia, abdominal obesity, hyperinsulinemia and a special type of dislipidemy, nowadays. Patients with AH associated with such metabolic disorders are at a higher risk of developing cardiovascular disease and diabetes. However, it is very difficult to achieve the target level of blood pressure in this category of patients. Usually, these patients should be treated using combination therapy at the beginning of the treatment. Drugs, which possess good antihypertensive effect, as well as an additional positive influence on metabolic parameters, for instance I2-imidazoline receptor agonists, can be used as the drugs of choice in combination with ACE inhibitorsor angiotensin II receptor blockersin this category of patients.
About the Authors
Yu. V. Zhernakova
A.L.Myasnikov Institute of Clinical Cardiology, Russian Cardiological Scientific-Industrial Complex of the Ministry of Health of the Russian Federation
Russian Federation
Russian Federation
G. H. Sharipova
A.L.Myasnikov Institute of Clinical Cardiology, Russian Cardiological Scientific-Industrial Complex of the Ministry of Health of the Russian Federation
Russian Federation
Russian Federation
I. E. Chazova
A.L.Myasnikov Institute of Clinical Cardiology, Russian Cardiological Scientific-Industrial Complex of the Ministry of Health of the Russian Federation
Russian Federation
Russian Federation
References
1. Демографический ежегодник России. 2013: Стат. сб. М.: Росстат, 2014.
2. Чазова И.Е., Жернакова Ю.В., Ощепкова Е.В. и др. от имени участников исследования. Распространенность факторов риска сердечно - сосудистых заболеваний в российской популяции больных артериальной гипертонией. Кардиология. 2014; 10: 4-12.
3. Mancia G, Fagard R, Narkiewicz K et al. 2013 ESH/ESC Guidelines for the Management of Arterial Hypertension. J Hypertens 2013; 31 (7): 1281-357.
4. International Diabetes Federation Diabetes Atlas Update 2013. 6th edition. www.idf.org/diabetesatlas.
5. Шарипова Г.М. Особенности поражения органов - мишеней у больных артериальной гипертонией в зависимости от наличия и отсутствия метаболического синдрома. Дис. … д - ра мед. наук. М., 2009.
6. Жернакова Ю.В. Клиническая характеристика различных вариантов течения метаболического синдрома и возможности влияния антигипертензивной терапии на уровень артериального давления, состояние углеводного, липидного обменов и выраженность ожирения у больных артериальной гипертонией и метаболическим синдромом. Дис. … д - ра мед. наук. М., 2012.
7. Красильникова Е.И., Баранова Е.И., Благосклонная Я.В. и др. Терапия артериальной гипертензии у больных с метаболическим синдромом. Справ. поликлин. врача. 2011; 9: 23-7.
8. Olivares-Reyes J.A, Arellano-Plancarte A, Castillo-Hernandez J.R. Angiotensin II and the development of insulin resistance: implications for diabetes. Mol Cell Endocrinol 2009; 302: 128-39.
9. Рекомендации по ведению больных артериальной гипертонией с метаболическими нарушениями. Кардиологический вестн. 2014; 1: 4-57.
10. Adler A.I, Stratton I.M, Neil H. et al. on behalf of the UK Prospective Study group. Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): prospective observational study. BMJ 2000; 321: 412-9.
11. Stamler J, Vaccaro O, Neaton J.D. et al. Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care 1993; 16 (2): 434-44.
12. Рациональная фармакотерапия сердечно - сосудистых заболеваний. Руководство для практикующих врачей. Под общей ред. Е.И.Чазова, Ю.А.Карпова. 2-е изд. М.: Литтерра, 2014.
13. Chazova I, Schlaich M.P. Improved hypertension control with the imidazoline agonist moxonidine in a multinational metabolic syndrome population: principal results of the MERSY Study. Int J Hypertens 2013; 2013: 1-9. doi:10.1155/2013/541689
14. Ryden L, Grant P.J, Anker S.D et al. ESC Guidelines on diabetes, prediabetes, and cardiovascular diseases developed in collaboration with the EASD. Diabetes and Vascular Disease Research 2014; 11 (3): 133-73. doi:10.1093/eurheartj/eht108
Review
For citations:
Zhernakova Yu.V., Sharipova G.H., Chazova I.E. Patients with arterial hypertension associated with metabolic disorders: characteristics and therapeutic approach. Systemic Hypertension. 2015;12(1):52-57. (In Russ.)
Views:
109
Email this article 